OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024

Research and Markets Report On OpportunityAnalyzer: Respiratory
Syncytial Virus (RSV) ­ Opportunity Analysis and Forecasts to 2024
The report analyzes and presents an overview of " OpportunityAnalyzer: Respiratory
Syncytial Virus (RSV) ­ Opportunity Analysis and Forecasts to 2024 ” worldwide.
Human respiratory syncytial virus (RSV) is an enveloped, single­stranded, negative­sense
ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus
was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying
symptoms of the common cold, and later from infants suffering from respiratory disease.
RSV can cause upper respiratory tract infections (the common cold) and is the most
important cause of lower respiratory tract infections, such as bronchiolitis and pneumonia,
in infants. RSV is also an important cause of hospitalizations and deaths in elderly adults.
Today, Medimmunes Synagis (palivizumab) is the only licensed intervention for the
prevention of RSV in infants at a high risk of severe infection. This humanized, mouse
monoclonal antibody (mAb) was first approval in 1998, and while it is an efficacious
prophylactic intervention, its short 20­day half­life necessitates monthly dosing during the
RSV season. Moreover, the high cost of Synagis limits its use to certain subgroups of infants
who are at high risk of severe RSV infection, and it is not indicated for use in elderly adults,
leaving a key population of high­risk individuals unprotected. Furthermore, due to the
absence of effective RSV­specific antivirals, the treatment of RSV infections is largely
restricted to a number of supportive treatment options. GlobalData projects the global RSV
marketplace ­ which, for the purposes of this report, comprises the seven major
pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) ­ to
experience unprecedented growth from 2014­2024, driven by the arrival of novel
approaches to prevention and management of RSV.
Download Sample copy of this Report at: :
http://www.marketresearchreports.biz/sample/sample/699481
Highlights
Key Questions Answered
• Based on interviews with key opinion leaders (KOLs), GlobalData has identified the
major unmet needs in the RSV marketplace. Will the leading pipeline agents fulfil
these unmet needs during the forecast period (2014­2024)?
• What research and development (R&D) strategies will companies leverage to

compete in the future RSV marketplace?
• Which patient population(s) are most likely to be targeted by novel RSV prophylactic
and therapeutic agents?
• What clinical and commercial factors are likely to influence RSV product uptake in
the 7MM?
Key Findings
• The global RSV marketplace ­ which, for the purposes of this report, encompasses
the sales of products for the prevention or treatment of RSV in the 7MM ­ was worth
approximately $640m in 2014. GlobalData projects the market to surpass $2.3bn in
sales by 2024, at a compound annual growth rate (CAGR) of 29.9% from 2014­
2024. The sales are projected to originate predominantly from the US (a 62% market
share), followed distantly by the 5EU (a 29% market share).
• The anticipated arrival of novel prophylactic mAbs that boast improved dosing
criteria compared with Synagis, led by MedImmunes MEDI8897, will be a principal
driver of RSV market growth across the 7MM. The licensure of the first adult vaccine
to offer protection against RSV, Novavaxs RSV­F Vaccine, will also stimulate rapid
growth in a previously untapped segment of the marketplace.
• A persistent lack of patient and physician awareness of RSV in adult patients ­
specifically the infections substantial impact on morbidity and mortality in the
elderly ­ will serve as a key impediment to market growth from 2014­2024.
Scope
• Overview of RSV infections, including epidemiology, etiology, pathophysiology,
symptoms, diagnosis, and current management strategies.
• Topline RSV market revenue from 2014­2024. Annual cost of therapy (ACOT) and
major pipeline product sales in this forecast period are included.
• Key topics covered include current treatment options, unmet needs and
opportunities, and the drivers and barriers affecting RSV product sales in the 7MM.
• Pipeline analysis: comprehensive data split across different phases, emerging novel
trends under development, synopses of innovative early­stage projects, and detailed
analysis of late­stage pipeline products.
• Analysis of the current and future market competition in the global RSV market.
Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to ­
• Develop and design your in­licensing and out­licensing strategies through a review
of pipeline products and technologies, and by identifying the companies with the
most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the
global RSV market.
• Drive revenues by understanding the key trends, innovative products and
technologies, market segments, and companies likely to impact the RSV market in
the future.

• Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create
effective counter­strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and
segments that present maximum opportunities for consolidations, investments, and
strategic partnerships.
Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 20
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and Pathophysiology 22
3.1.1 Etiology 22
3.1.2 Pathophysiology 26
3.2 Symptoms and Prognosis 28
3.2.1 Symptoms 28
3.2.2 Prognosis 30
3.3 Quality of Life 31
3.4 Disease Management 31
3.4.1 Diagnosis of RSV Infection 32
3.4.2 Prevention of RSV Infection 34
3.4.3 Treatment of RSV Infection 37
4 Epidemiology 40
About us
MarketResearchReports.biz is the most comprehensive collection of market research
reports. MarketResearchReports.Biz services are specially designed to save time and money
for our clients. We are a one stop solution for all your research needs, our main offerings
are syndicated research reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1­518­621­2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz